Podcast: Access affordability
is is the fourth episode in our Insights Uncovered: A Real-World Data Podcast Series, exploring the evolving landscape of real-world…
Partner Content
-
-
What causes white space in early-stage drug development?
White space refers to unproductive gaps in drug development, when progress stalls due to scientific barriers or because of process,…
-
Sharp Services invests $100 million in US and European facilities to increase capacity and service offerings
Sharp Services, a leader in pharmaceutical packaging, clinical trial services and sterile manufacturing has announced a $100 million investment across its…
-
Podcast: Charting the next chapter in obesity therapeutics
Obesity is a complex, chronic disease affecting hundreds of millions of people across diverse populations. Recent advances in incretin biology…
-
Forced degradation studies: A critical lens into pharmaceutical stability
Forced degradation studies simulate harsh conditions to accelerate degradation, helping us uncover potential vulnerabilities in a molecule’s structure and predict…
-
Therapeutic Radiopharmaceuticals: Download 2025 Global Report
Key insights include: Precision oncology advances driving radiopharmaceutical innovation and adoption. Rising global trial activity and early-phase development. Strong market…
-
Could AI help avoid unpredictable and high placebo response rates in pain trials?
According to the CDC, an estimated 20.9% of the US adult population experienced chronic pain in 2021, while 6.9% were…
-
ESMO 2025: Data, decisions, and the future of oncology
This year’s congress showcased remarkable progress across multiple fronts, from next-generation immunotherapies and antibody-drug conjugates (ADCs) to the accelerating role of AI-driven…
-
Podcast: Managing complexities and challenges in early-phase clinical trials
Among the many challenges for clinical trial project teams, logistics is one of the most critical and complex. From project…
-
Turning bottlenecks into breakthroughs in gene therapy manufacturing
In late 2023, the first CRISPR-based gene therapy for sickle cell disease patients Casgevy, received the seal of approval from…